pharmaphorum

OCTOBER 2, 2020

The five new NHS Patient Recruitment Centres (NPRCs) are set to shape the future of commercial clinical trials in the UK by offering new ways to conduct late-phase, large-scale research projects.

Clinical Trials 52

Clinical Trials Clinical Trials Life Science Clinical Research 52

The Pharma Data

SEPTEMBER 29, 2021

Heerspink, Professor of Clinical Trials and Personalized Medicine and a clinical pharmacologist/trialist at the Department of Clinical Pharmacy and Pharmacology at the University center Groningen, Netherlands, and Co-Chair of the study’s Executive Committee.

Clinical Development 52

Clinical Development Development Clinical Trials Clinical Trials 52

The Pharma Data

FEBRUARY 21, 2022

Our leadership in cardiology, radiology and women’s health is recognized worldwide, and we are expanding our presence in oncology, working tirelessly to bring forward new approaches that can change the treatment paradigm for patients,” said Stefan Oelrich, Member of the Board of Management, Bayer AG and President of Bayer’s Pharmaceuticals Division.

Radiology 52

Radiology Cardiology Development Production 52

The Pharma Data

MAY 31, 2022

the completion of enrollment of its Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with Parkinson’s disease (PD). Ph1 clinical trial is to evaluate the safety, tolerability, and?preliminary?efficacy?of Senior Vice President, Clinical Development, BlueRock Therapeutics.

Trials 52

Trials Engineer Clinical Trials Clinical Trials 52

pharmaphorum

FEBRUARY 8, 2022

We live in a diverse world and our teams, clinical trial participants, customers, and key opinion leaders (KOLs) should reflect this. Diversity in clinical trials. Racial disparities are still commonplace in most clinical trials. Are decentralised and virtual trials the answer? Diverse teams.

Clinical Trials 116

Clinical Trials Clinical Trials Trials Cardiology 116

Pharma Marketing Network

JANUARY 12, 2023

Liz Paulson, Associate Vice President, Life Sciences for the Healthcare Business of LexisNexis® Risk Solutions, is recognized with HBA’s Strategic Transformation Achievement Recognition (STAR) volunteer honor. Christi Shaw, Chief Executive Officer, Kite, a Gilead Company, was selected as the 2023 Woman of the Year.

Life Science 52

Life Science Manufacturing Cardiology Development 52

XTalks

JULY 10, 2023

We did not get a Class II certification for diabetes only, or orthopedics or cardiology; we got a disease-agnostic certification. Now, as we develop new predictive algorithms, whether that is in diabetes, cardiology, respiratory or oncology, we can bring those algorithms to our platform because it is disease-agnostic.

Life Science 52

Life Science Cardiology Regulation Pharma Companies 52

XTalks

FEBRUARY 8, 2024

Diabetes remains a critical global challenge, affecting millions of lives and commanding significant attention from the medical, life sciences and pharmaceutical sectors. The efficacy and safety of Rybelsus in reducing blood sugar in patients with type 2 diabetes were investigated in various clinical trials.

Sales 52

Sales Insulin FDA Approval Drugs 52

XTalks

FEBRUARY 9, 2024

For healthcare professionals and stakeholders in the life sciences sector, understanding the top-performing cardiovascular drugs is not just about recognizing their financial success. The clinical benefits and safety of Repatha have been studied for 12 years in 50 clinical trials with over 47,000 patients.

Sales 59

Sales FDA Approval Drugs Marketing 59

XTalks

APRIL 15, 2021

Late-stage clinical trial failures are largely to blame for the lack of effective treatment options for patients with HFpEF, and poor five-year survival rates make this an area of great unmet need. Heart failure affects about 6.2

Development 98

Development Drugs Genome Genomics 98

XTalks

AUGUST 2, 2023

With Blackstone Life Sciences, up to €300 million (around $315 million USD) will be invested to accelerate pivotal studies and clinical development programs for formulating the subcutaneous delivery of the anti-CD38 antibody Sarclisa (isatuximab) for the treatment of multiple myeloma. billion ($3.65 billion ($2.85

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

JANUARY 19, 2024

Currently, several alpha particle emitters are being investigated in clinical trials. Radiobiological Considerations of Alpha Emitters: No Two Are the Same While Xofigo (Ra-223) remains the only FDA-approved alpha emitter, several others are being investigated in both clinical trials and preclinical studies.

DNA 66

DNA Radiology FDA Approval Development 66